GlassScriptPhysician profile
Yongli Ji
NPI 1659526812
$2,641.81
in general payments reported to CMS, 2019-2025
11 companies · $265 in 2025
The $265 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $12.79 · 2021: $32.92 · 2022: $60.95 · 2023: $1,943 · 2024: $181 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,943 · Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,942.50 |
| Food and Beverage | $445.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,942.50 | 2023 | Enhertu |
| Beone Medicines USA, INC. | $133.50 | 2025 | Tevimbra |
| Stemline Therapeutics INC. | $131.44 | 2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $130.80 | 2024 | Rezlidhia, Tavalisse |
| Taiho Oncology, INC. | $117.65 | 2019 | |
| Pfizer INC. | $50.26 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $50.00 | 2024 | Onivyde |
| Daiichi Sankyo INC. | $42.52 | 2022 | |
| Janssen Biotech, INC. | $18.43 | 2022 | |
| Genentech USA, INC. | $12.79 | 2020 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yongli Ji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.